Adam R. Craig - Jun 1, 2022 Form 4/A - Amendment Insider Report for CTI BIOPHARMA CORP (CTIC)

Role
President and CEO, Director
Signature
Adam R. Craig
Stock symbol
CTIC
Transactions as of
Jun 1, 2022
Transactions value $
$0
Form type
4/A - Amendment
Date filed
6/3/2022, 07:15 PM
Date Of Original Report
Jun 3, 2022
Previous filing
Mar 11, 2022
Next filing
Jul 6, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -27K -2.08% $0.00 1.27M Jun 1, 2022 Common Stock 27K $0.84 Direct F1, F2
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -27K -2.12% $0.00 1.25M Jun 2, 2022 Common Stock 27K $0.84 Direct F1, F2
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -18.2K -1.46% $0.00 1.23M Jun 3, 2022 Common Stock 18.2K $0.84 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Form 4/A amends the description of Title of Derivative Security previously reported on Form 4 filed on 6-3-2022.
F2 One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.